Binczak Marie, Fischler Marc, Le Guen Morgan
From the Department of Anesthesiology, Hospital Foch, Suresnes, France.
University Versailles Saint-Quentin en Yvelines, France.
A A Pract. 2019 Jul 1;13(1):17-19. doi: 10.1213/XAA.0000000000000973.
The curative role of sugammadex has been challenged in several observations of rocuronium-induced anaphylaxis because sugammadex may not completely encapsulate the molecule of rocuronium. In such conditions, rocuronium remains able to cause immunoglobulin E cross-linkage and the anaphylaxis mechanism can continue. We describe a case of rocuronium-induced anaphylaxis in which clinical improvement followed sugammadex administration. Intradermic skin tests confirmed rocuronium immunoglobulin E-mediated anaphylaxis but also showed intradermal injection of mixing in equal molecular ratio of sugammadex with rocuronium preventing rocuronium anaphylactic skin reaction. This observation demonstrates the efficacy of sugammadex to prevent rocuronium interaction with the skin immune system.
在罗库溴铵诱导的过敏反应的多项观察中,舒更葡糖钠的治疗作用受到了质疑,因为舒更葡糖钠可能无法完全包裹罗库溴铵分子。在这种情况下,罗库溴铵仍能够引起免疫球蛋白E交联,过敏反应机制可能会持续。我们描述了1例罗库溴铵诱导的过敏反应病例,该病例在给予舒更葡糖钠后临床症状得到改善。皮内皮肤试验证实了罗库溴铵免疫球蛋白E介导的过敏反应,但也显示以等分子比例将舒更葡糖钠与罗库溴铵混合进行皮内注射可预防罗库溴铵过敏皮肤反应。这一观察结果证明了舒更葡糖钠预防罗库溴铵与皮肤免疫系统相互作用的有效性。